Rupam Manna/LinkedIn
Aug 17, 2026, 00:33
Rupam Manna: CELMoDs – Next-Generation Molecular-Glue Protein Degraders
Rupam Manna, Postdoctoral Student – DrNB Medical Oncology at National Board of Examinations, shared a post on X:
“CELMoDs: next-generation molecular-glue protein degraders.
By binding cereblon, CELMoDs redirect the CRL4–CRBN E3 ubiquitin ligase toward IKZF1 and IKZF3.
Their proteasomal degradation suppresses IRF4–MYC signalling, promotes myeloma-cell apoptosis and activates T and NK cells.
Key agents:
- Iberdomide – first FDA-approved CELMoD
- Mezigdomide – investigational in multiple myeloma
- Golcadomide – investigational in lymphoma
Remember the major class toxicities: neutropenia, infections, anaemia and thrombocytopenia.”

Stay updated with Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?